Cargando…

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer

BACKGROUND: Osteoporosis is a skeletal disorder characterized by compromised bone strength, resulting in increased fracture risk. Patients with prostate cancer may have multiple risk factors contributing to bone fragility: advanced age, hypogonadism, and long-term use of androgen-deprivation therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussain, Arif, Tripathi, Abhishek, Pieczonka, Christopher, Cope, Diane, McNatty, Andrea, Logothetis, Christopher, Guise, Theresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134041/ https://www.ncbi.nlm.nih.gov/pubmed/33028943 http://dx.doi.org/10.1038/s41391-020-00296-y

Ejemplares similares

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers
por: Fang, Dong, et al.
Publicado: (2019)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years
por: Shida, Yohei, et al.
Publicado: (2017)

CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions
por: Joshi, Molishree, et al.
Publicado: (2019)

Androgen deprivation-induced OPHN1 amplification promotes castration-resistant prostate cancer
por: Liu, Junjiang, et al.
Publicado: (2022)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
por: D'Amico, Anthony V., et al.
Publicado: (2021)

Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer
por: Forster, Rachel B., et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

How do we define “castration” in men on androgen deprivation therapy?
por: Itty, Sarin, et al.
Publicado: (2020)

Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer
por: Subudhi, Sumit K, et al.
Publicado: (2015)

Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
por: Ma, Ting Martin, et al.
Publicado: (2023)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
por: Merseburger, Axel S., et al.
Publicado: (2014)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?
por: Niklas, Christina, et al.
Publicado: (2021)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer
por: Zhang, Jingsong, et al.
Publicado: (2022)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
por: Titus, Mark A., et al.
Publicado: (2012)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases
por: Varenhorst, Eberhard, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_03nnt4n4i2ptumd18hj5mecgq6